Formycon AG (ETR:FYB)
22.60
+1.30 (6.10%)
May 29, 2026, 5:35 PM CET
Formycon AG Revenue
Formycon AG had revenue of 13.10M EUR in the quarter ending March 31, 2026, with 191.21% growth. This brings the company's revenue in the last twelve months to 52.28M, down -13.91% year-over-year. In the year 2025, Formycon AG had annual revenue of 44.48M, down -36.17%.
Revenue (ttm)
52.28M
Revenue Growth
-13.91%
P/S Ratio
7.64
Revenue / Employee
257.52K
Employees
203
Market Cap
399.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.48M | -25.20M | -36.17% |
| Dec 31, 2024 | 69.67M | -8.02M | -10.32% |
| Dec 31, 2023 | 77.70M | 35.20M | 82.83% |
| Dec 31, 2022 | 42.50M | 5.88M | 16.07% |
| Dec 31, 2021 | 36.61M | 2.32M | 6.76% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.24B |
| Siemens Healthineers AG | 23.07B |
| Fresenius SE & Co. KGaA | 22.99B |
| Merck KGaA | 20.96B |
| Redcare Pharmacy NV | 3.07B |
| Medios AG | 2.12B |
| RHÖN-KLINIKUM Aktiengesellschaft | 2.00B |
| MEDICLIN Aktiengesellschaft | 810.48M |
Formycon AG News
- 3 days ago - Formycon AG Earnings Call Transcript: Q1 2026 - Transcripts
- 3 days ago - Formycon AG Earnings release: Q1 2026 - Filings
- 3 days ago - Formycon AG Slides: Q1 2026 - Filings
- 3 days ago - EQS-News: Formycon Reports Positive Operational Progress and Strong Revenue Growth in the First Quarter of 2026 - Wallstreet:Online
- 9 days ago - EQS-AFR: Formycon AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements - Wallstreet:Online
- 10 days ago - EQS-News: Formycon invites to conference call on the results of the first quarter of 2026 and announces participation in international investor conferences - Wallstreet:Online
- 12 days ago - EQS-News: Formycon expands commercial portfolio: Aflibercept biosimilars Ahzantive and Baiama are now available in the European Union - Wallstreet:Online
- 5 weeks ago - Formycon AG Earnings Call Transcript: Q4 2025 - Transcripts